Overexpression of PAD4 suppresses drug resistance of NSCLC cell lines to gefitinib through inhibiting Elk1-mediated epithelial-mesenchymal transitionQiong Duan(Xijing Hospital), Wenchao Liu(Air Force Medical University)Oncology ReportsApril 28, 201610.3892/or.2016.4780Cited by 29SaveCiteExport RISWatch citationsRelated PapersMetformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma|BMC Cancer|2014|61